Here are the findings after Jefferies & Company Inc. analyst James Vane-Tempest takes a closer look at the Fresenius SE paper.
The analysis house Jefferies raised the price target for Fresenius from 40 to 44 euros ahead of the fourth quarter and left the rating at “Buy”. Analyst James Vane-Tempest increased the sales estimate for the hospital operator and medical manufacturer in a study available on Wednesday. With a higher estimate of earnings per share, he took into account the company’s cost savings.
Stock valuation in detail: The Fresenius SE share and its development on the day of the analysis
The share gained 0.9 percent to EUR 35.13 at 9:37 a.m. in the XETRA session. The share certificate therefore still has room for growth of 25.25 percent based on the set price target. Most recently, 120,929 Fresenius SE shares were traded via XETRA. The paper has gained 4.7 percent since the beginning of 2025. Fresenius SE is expected to present its profit and sales figures for Q4 2024 on March 26, 2025.
NEW YORK (dpa-AFX Analyzer) / editorial team finanzen.net
Original study published: January 15, 2025 / 3:06 p.m. / ET
First distribution of the original study: January 15, 2025 / 7:00 p.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenstellenpflicht/ disclosure_duty.html.
Selected leverage products on Fresenius
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Fresenius
The leverage must be between 2 and 20
Advertising